Barclays dodges monoline threat with $12.3bn asset spin-off to Protium fund

© 2026 GlobalCapital, Derivia Intelligence Limited, company number 15235970, 4 Bouverie Street, London, EC4Y 8AX. Part of the Delinian group. All rights reserved.

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement | Event Participant Terms & Conditions

Barclays dodges monoline threat with $12.3bn asset spin-off to Protium fund

Barclays this week took flak from some quarters for a $12.3bn spin off of monoline-wrapped structured finance assets. It attracted the criticism for what looked like accounting sleight of hand used to mitigate mark-to-market effects even though it gave a thorough explanation of the transaction and committed to maintaining a high degree of transparency.

Unlock this article.

The content you are trying to view is exclusive to our subscribers.

To unlock this article:

Request demo or Login
  • 4,000 annual insights
  • 700+ notes and long-form analyses
  • 4 capital markets databases
  • Daily newsletters across markets and asset classes
  • 2 weekly podcasts
Gift this article